SynthesisMedicine2020
The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis.
Synthesis in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.Radiation oncology (London, England) · 2023Guideline
- Time-dependent prognostic value of automated Ki67 assessment and its integration with molecular risk profiling in WHO grade 2 meningioma.Acta neuropathologica communications · 2026Article
- Article
- Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.Journal of neuropathology and experimental neurology · 2026Article
- The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients.Acta neurochirurgica · 2026Article
- Double Staining Immunohistochemistry and Digital Pathology: Moving Towards Standardization of the Proliferative Index Evaluation in Meningiomas.Journal of personalized medicine · 2026Article
- Prognostic relevance of MIB-1 labeling index in VHL-associated and sporadic spinal hemangioblastomas: a subgroup analysis from a multicentric study.Acta neuropathologica communications · 2025Article
- Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.Acta neurochirurgica · 2025Article
- Clinico-Histomorphological and Mib-1 Analysis of Recurrent Meningiomas: A Retrospective Study.Asian journal of neurosurgery · 2025Article
- Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections.Journal of neuropathology and experimental neurology · 2025Article
- MUC4 and Caspase-3 Immunoexpression in Meningioma: A Histopathological Study Linking Mucin & Apoptotic Pathways.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Multiplexed sensitivity encoding diffusion-weighted imaging in the assessment of meningiomas: improving the image quality, grading accuracy, and proliferative activity evaluation.Quantitative imaging in medicine and surgery · 2025Article
- Article
- Is There Any Correlation Between Diffusion-Weighted Imaging and Histopathologic Findings of Meningioma? A Retrospective Study.Health science reports · 2025Article
- The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management.Journal of neuro-oncology · 2025Article
- Immunohistochemical Staining Properties of Osteopontin and Ki-67 in Feline Meningiomas.Animals : an open access journal from MDPI · 2024Article
- The Prognostic Role of Fibulin-2 and Ki-67 Index in Patients with Meningioma: A Study among Minangkabau Ethnicity.Asian Pacific journal of cancer prevention : APJCP · 2024Observational
- Functional precision medicine assay for recurrent meningioma: a proof of principle. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Single versus multiple reoperations for recurrent intracranial meningiomas.Journal of neuro-oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKi-67 is a typical immunohistochemical marker for cell proliferation. Higher expression of Ki-67 is correlated with poor clinical outcomes in several cancers. However, the prognostic value of Ki-67 on the prognosis of meningiomas is still controversial. The purpose of this meta-analysis was to evaluate the prognostic value of Ki-67 in meningiomas. METHODS AND MATERIALS: We searched Medline and EMBASE from inception to December 31, 2018, to identify relevant articles. Using a fixed or random effects model, pooled hazard ratios (HRs) for overall survival (OS) and disease/progression/recurrence-free survival (D/P/RFS) were estimated.
resultsA total of 43 studies, comprising 5012 patients, were included in this analysis. Higher Ki-67 expression levels were significantly associated with worse OS (HR = 1.565; 95% CI: 1.217-2.013) and D/P/RFS (HR = 2.644; 95% CI: 2.264-3.087) in meningiomas. Subgroup analysis revealed that all the included factors (ethnicity, tumor grade, HR sources, definition of cutoffs, cutoff values) for heterogeneity investigation can affect the pooled results. Among them, the definitions of cutoffs and cutoff values factor are the two main contributors toward heterogeneity. Multivariable meta-regression analysis also showed that methodologies used for cutoff value definition contributed to the high inner-study heterogeneity.
conclusionsHigher Ki-67 expression levels negatively influenced survival in meningiomas. A higher cutoff value (>4%) is more appropriate for prognosis prediction. It is highly recommended that Ki-67 expression profile could be assessed in meningiomas treatment for predicting survival. And patients with elevated expression of Ki-67 need to have close follow-ups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.